TY - JOUR
T1 - Acquisition of Cross-Resistance to Bedaquiline and Clofazimine following Treatment for Tuberculosis in Pakistan
AU - Ghodousi, Arash
AU - Rizvi, Alamdar Hussain
AU - Baloch, Aurangzaib Quadir
AU - Ghafoor, Abdul
AU - Khanzada, Faisal Masood
AU - Qadir, Mehmood
AU - Borroni, Emanuele
AU - Trovato, Alberto
AU - Tahseen, Sabira
AU - Cirillo, Daniela Maria
PY - 2019/1/1
Y1 - 2019/1/1
N2 - We report on the first six cases of acquired resistance to bedaquiline in Pakistan. Seventy sequential isolates from 30 drug-resistant-tuberculosis patients on bedaquiline-containing regimens were retrospectively tested for bedaquiline resistance by MIC testing and by the detection of mutations in relevant genes. We documented cases failing therapy that developed specific mutations in Rv0678 and had increased MICs associated with cross-resistance to clofazimine during treatment. This study underlines the relevance of surveillance programs following the introduction of new drugs.
AB - We report on the first six cases of acquired resistance to bedaquiline in Pakistan. Seventy sequential isolates from 30 drug-resistant-tuberculosis patients on bedaquiline-containing regimens were retrospectively tested for bedaquiline resistance by MIC testing and by the detection of mutations in relevant genes. We documented cases failing therapy that developed specific mutations in Rv0678 and had increased MICs associated with cross-resistance to clofazimine during treatment. This study underlines the relevance of surveillance programs following the introduction of new drugs.
KW - Antibiotic resistance
KW - Bedaquiline
KW - Clofazimine
KW - Multidrug resistance
KW - Tuberculosis
KW - Whole-genome sequencing
KW - XDR
UR - http://www.scopus.com/inward/record.url?scp=85071270237&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071270237&partnerID=8YFLogxK
U2 - 10.1128/AAC.00915-19
DO - 10.1128/AAC.00915-19
M3 - Article
C2 - 31262765
AN - SCOPUS:85071270237
VL - 63
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
SN - 0066-4804
IS - 9
M1 - e00915-19
ER -